Kiadis Pharma Wins Orphan Drug Designation for Transplant Drug
Posted on: Wednesday, 24 September 2008, 12:00 CDT
Kiadis Pharma, an oncology focused pharmaceutical development company, has announced that its lead product Atir has received orphan drug designation from the European Medicines Agency for the prevention of acute graft versus host disease following an allogeneic bone marrow transplantation.
The European Medicines Agency's orphan drug designation is reserved for new therapies being developed to treat life-threatening or chronically debilitating diseases or conditions that are relatively rare in the EU and for which no satisfactory therapy is available.
The orphan drug designation provides for incentives to support research and development, exemption from user fees and a 10-year period of market exclusivity in the EU after product approval.
Manja Bouman, CEO of Kiadis Pharma, said: "Following the orphan drug designation granted by the FDA for our lead product Atir, this is another important milestone in the development of Atir as a novel approach which may enable a safe and potentially life-saving mismatched bone marrow transplantation as a treatment option for end-stage blood cancer patients."
Source: Datamonitor
Related Articles
- Cohera Medical Receives ISO 13485 Certification: Company Meets International Standards for Design, Development and Manufacturing of Medical Devices
- Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development
- Saft and ESMA to Cooperate on Supercapacitor Development, Production and Commercialization
- EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
- Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
- Indivumed Announces New Product: Automated Immunohistochemistry Services for the Drug Discovery and Development Market
- Icagen Announces New Members of Drug Discovery and Development Expert Panel
- Michael J. Fox Foundation Launches Drug Discovery and Development Initiative
- Drug Safety to Be a Primary Focus at 10th Annual Drug Discovery Technology(R) & Development World Congress
- ViroLogic Announces Multi-Year Service Agreement With Schering-Plough to Support New HIV Drug Discovery and Development Efforts
 |
 |
User Comments (0)
RSS Feeds